



HHS Public Access

Author manuscript

Front Oral Maxillofac Med. Author manuscript; available in PMC 2022 July 08.

Published in final edited form as:

Front Oral Maxillofac Med. 2022 June ; 4: . doi:10.21037/fomm-21-10.

Potential application of dental stem cells in regenerative reconstruction of oral and maxillofacial tissues: a narrative review

Puhan He¹, Qunzhou Zhang¹, Faizan I. Motiwala², Rabie M. Shanti^{1,3,4}, Brian M. Chang^{1,5}, Anh D. Le^{1,3}

¹Department of Oral & Maxillofacial Surgery & Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

²University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

³Department of Oral & Maxillofacial Surgery, Penn Medicine Hospital of the University of Pennsylvania, Philadelphia, PA, USA

⁴Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

⁵Division of Restorative Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

Abstract

Background and Objective: Oral and maxillofacial (OMF) defects caused by congenital conditions, injuries, ablative surgery for benign and malignant head & neck tumor, can often lead to OMF deformities and malfunctions in speech, mastication/chewing, and swallowing as well as have deleterious psychological effects and socioeconomic burdens to patients. Due to the unique complex 3D geometry of the head and neck region, reconstruction and rehabilitation of OMF defects remain a major challenge for OMF surgeons.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

Correspondence to: Anh D. Le, DDS, PhD. Department of Oral & Maxillofacial Surgery, Penn Medicine Hospital of the University of Pennsylvania, Philadelphia; Department of Oral & Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA. Anh.Le@pennmedicine.upenn.edu; Qunzhou Zhang, PhD. Department of Oral & Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104, USA. zqunzhou@upenn.edu.

Contributions: (I) Conception and design: P He, Q Zhang, AD Le; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at <https://fomm.amegroups.com/article/view/10.21037/fomm-21-10/rc>

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The purpose of this narrative review is to update the information on the biological properties and functions of mesenchymal stem cells derived from various dental tissues (dental-MSCs) and their potential application in tissue engineering (TE) and regenerative reconstruction of OMF tissues.

Methods: A data-based search was performed by using PubMed database whereby articles published between 2000 and 2021 in English were included in the search with the following key words: dental stem cells, OMF reconstruction, OMF TE and regeneration.

Key Content and Findings: Currently, the advancement in stem cell biology, biomaterial science, and TE technology has demonstrated the significant potential application of stem cell-based therapy in regenerative reconstruction and rehabilitation of OMF defects. However, no stem cell-based product or device has been translated into clinical application to replace microsurgical free tissue transfer, the current mainstay of care in the reconstruction of OMF defects.

Conclusions: Currently, microsurgical free tissue transfer remains the gold standard mainstay of care for the reconstruction of OMF defects due to their abundant blood supply and flexibility for transplantation. However, several major challenges, such as the limited availability, the requirement of a second surgery, donor site morbidity, and the risk of free flap failure, have promoted the development of novel approaches. Due to the advancement in stem cell biology, biomaterial science, and TE technology, stem cell-based regenerative therapy is emerging as a promising therapeutic approach for a variety of diseases, including regenerative reconstruction and rehabilitation of OMF defects. In this narrative review, we update on the characteristics and biological functions of mesenchymal stem cells derived from various dental tissues (dental-MSCs) and their released cell-free products, extracellular vesicles (EVs). We also highlighted their potential application in TE and regenerative reconstruction of OMF defects in animal models and clinical studies and the potential challenges in this field.

Keywords

Dental stem cells; extracellular vesicles (EVs); tissue engineering (TE); regenerative therapy; oral and maxillofacial (OMF) defect

Introduction

Reconstructive surgery is a growing aspect of oral and maxillofacial (OMF) surgery specialty. Among others, OMF surgeons are especially equipped to manage deformities and defects of the midface/maxilla, oromandibular region, and the temporomandibular joint (1-4). Defects in the head and neck may involve insult to multiple tissue types including bones, cartilage, muscle, skins, nerves and blood vessels. The complex anatomy and the presence of specialized organs such as the tongue, periodontium, and teeth (5-8) make reconstruction of this region especially challenging. OMF defects and deformities may be acquired, as a sequela of trauma and surgical resection due to neoplasm, infection or necrosis; or they may be congenital, as is in the case of cleft lips and palates (2). These defects result in facial disfigurement, speech impairment, mastication and swallowing difficulties, posing a significant psychological and economical burden to the patient and family (2,7,9-12). Reconstruction offers possibility of restoring function and cosmesis, and thereby improving overall quality of life (9,13,14).

In recent years, the development and advancement of state-of-the-art technologies and approaches, such as navigation, virtual surgical pre-planning (VSP), 3D printing technology, and microsurgical techniques have significantly advanced the field of OMF reconstruction (8,15). A successful reconstruction and functional rehabilitation of OMF defects rely on multiple factors, such as the type of defect, the health status of patients, and the treatment modality (13,15). Treatment modalities may include primary closure, healing by secondary intention, autografts, allograft, prosthesis and flaps. Locoregional flaps and vascularized soft-tissue and bone/composite free flaps are the mainstay of treatment for reconstruction of large OMF defects (16-20). However, donor site morbidity, and the inability to restore specialized tissue such as taste, sensory and periodontium pose challenges in reestablishing premorbid form and function (19). Therefore, further investigation on reconstruction surgery and functional rehabilitation techniques is requisite (13,15).

In the last decade, advancements in tissue engineering (TE), biomaterial science, and stem cell biology, have shed new light on the development of novel approaches for OMF reconstruction and functional rehabilitation (8). Regenerative medicine (RM) aims to use multiple approaches to replace or regenerate damaged cells, tissues and organs; or to stimulate the body's endogenous repair mechanisms (21). As an emerging field, RM integrates TE, material science, and stem cell biology to generate stem cell-based TE/RM products to meet the increasing clinical demand for tissue regeneration/reconstruction, including regenerative rehabilitation of OMF defects (22-24). This article reviews recent progress and potential towards the clinical application of stem cells, particularly, oral tissue-derived stem cells, in reconstructive surgery and regenerative rehabilitation in patients with OMF defects. We present the following article in accordance with the Narrative Review reporting checklist (available at <https://fomm.amegroups.com/article/view/10.21037/fomm-21-10/rc>).

Methods

In this narrative review, we searched the PubMed database using the following key words: dental stem cells, OMF reconstruction, OMF TE, oral craniofacial and maxillofacial tissue regeneration. The following MeSH terms were utilized to aid in the literature search as well: head and neck neoplasms, oral surgery, mesenchymal stem cells (MSCs), and TE. The published articles with full-text from Jan 2000 to Jan 2021 were included (Table 1) dental stem cells, OMF reconstruction, OMF tissue engineering and regeneration.

Discussion

MSCs

MSCs represent a population of multipotent postnatal stem cells with self-renewal and multipotent differentiation capabilities. The first isolated and most well characterized source of MSCs was from bone marrow (25). They are described as fibroblast-like in morphology and able to form adherent "colony-forming units-fibroblastic" (CFU-F) (26,27). Thereafter, the International Society of Cell & Gene Therapy (ISCT) defined human MSCs based on three minimal criteria,: (I) an adherent fibroblast-like appearance; (II) the expression of a panel of specific mesenchymal cell surface molecules such as CD73, CD90, and CD105,

while lacking the expression of hematopoietic cell markers such as CD34, CD45, CD11b, CD14, CD19, and of human leukocyte antigen-D related (HLA-DR or HMC-II) surface molecules; (III) the potential to differentiate into trilineage of mesodermal cells, including osteocytes, adipocytes, and chondrocytes (28). In addition to bone marrow, a similar population of MSCs have been isolated and characterized from various types of connective tissues throughout the body, including but not limited to, adipose tissue (29), lung (30), skin (31), peripheral blood (32), synovial fluids (33), and skeletal muscle (34). MSCs have also been identified from placenta (35), umbilical cord (36) and more recently, orofacial and dental tissues as well (37,38). In the last two decades, numerous preclinical and clinical studies have demonstrated that endogenous MSCs play essential roles in tissue homeostasis and remodeling (39), while exogenous MSCs expanded *ex vivo* have been widely utilized in TE/RM. In addition to facilitating repair/regeneration of damaged tissue through its multipotency, MSCs have also been sourced for its immunomodulatory properties to treat inflammatory diseases such as graft-versus host disease, multiple sclerosis, Crohn's disease, amyotrophic lateral sclerosis, among others (40-42).

New paradigm of MSC action: the secretome and extracellular vesicles (EVs)

Initially, it was thought that MSC-mediated regenerative therapeutic potentials are due to their multipotency as replacement cells to those injured/damaged cells. However, accumulating evidence indicates that clinical improvement can be achieved despite a limited number of MSCs engrafted and retained in the targeted tissues as well as the short survival time following their systemic or local transplantation. This suggests that MSC-mediated benefits might be due to their paracrine trophic effects (43). A growing body of evidence has demonstrated that MSCs exert their regenerative therapeutic effects mainly through their potent immunomodulatory/anti-inflammatory functions and pleiotropic effects mediated by their paracrine secretion of an array of soluble factors, such as cytokines, growth factors, hormones, miRNAs, and other bioactive small molecules. These factors have diverse biological functions, including but not limited to: (I) modulating both the local and systemic immune systems; (II) promoting angiogenesis; (III) promoting proliferation and survival of specific tissue resident cells; (IV) anti-apoptosis; (V) antioxidant effects, and so on (42-44). In 2019, ISCT accordingly added two more criteria to define MSCs, including their tissue of origin and related functional assays to determine their potential mechanism of action (MOA) (45).

EVs are nano-sized particles secreted by all types of cells, including MSCs, which play critical roles in intercellular communication through horizontal transfer of cargoes containing lipids, nucleic acids (DNA and RNA), proteins, and metabolites, etc. (46). Due to their biogenesis, size, and surface markers, EVs are generally classified into ectosomes and exosomes (47). Ectosomes, including microvesicles, microparticles, and large vesicles, are generated by the direct outward budding of the plasma membrane with a size ranged from ~50 to 1,000 nm in diameter, while exosomes are derived from endosomes with a size ranged from ~40 to 160 nm in diameter (~100 nm in average) (46). Accumulating evidence has shown that mesenchymal stem cell EVs (MSC-EVs) have pleiotropic effects on various biological processes of targeted cells, among which are immune responses, apoptosis, survival and proliferation, migration, lineage-specific

differentiation, and angiogenesis (44,46,48). Numerous pre-clinical studies have shown that systemic or local administration of MSC-EVs display potent regenerative and therapeutic potentials for a variety of pathological conditions, thus supporting the notion that MSC-EVs could provide promising avenues to generate cell-free products applicable for TE and RM (44,48), including their application in OMF TE and regeneration (49).

MSCs derived from dental tissues

Of interest, a unique population of MSCs has also been isolated from various dental tissues (Figure 1). As early as in 2000, the first type of MSCs was isolated from human dental pulp stem cells (DPSC) (50). Afterwards, MSCs have been isolated from other dental tissues, including exfoliated deciduous teeth (SHED) (51), periodontal ligament (PDLSC) (52), gingiva (GMSC) (53), apical papilla (SCAP) (54), dental follicle (DFSC) (55), and tooth germ stem cells (TGSC) (56). Similar to other sources of MSCs, such as BMSCs and ADSCs, these dental MSCs also possess potent self-renewal, multipotent differentiation, and immunomodulatory capacities (37,57,58) (Figure 1). During vertebrate embryonic development, most cranial/dental tissues are derived from neural crest (NC) (59,60). In recent years, studies have shown that a subpopulation of multipotent MSCs derived from human DPSCs (50,61), oral mucosa and gingiva (62-65), apical papilla (APSC) (66), DFSC (67), and PDLSC (68), are endowed with NC stem cell-like properties. Interestingly, as compared with mesoderm-derived MSCs, NC-derived MSC counterparts showed elevated differentiation potentials into neural cells and chondrocytes and enhanced immunomodulatory and anti-inflammatory effects both *in vitro* and *in vivo* (69). These studies suggest that dental tissues serve as important reservoirs of adult NC-derived multipotent stem cells. Recently, several lines of evidence have also demonstrated the pleiotropic effects and regenerative and therapeutic potentials of EVs secreted by dental-MSCs (70-72) (Figure 1). Together, dental MSCs represent an easily accessible source of MSCs with great potential application in TE/RM, particularly, in OMF tissue regeneration (49).

Application of dental MSCs in TE and regeneration of OMF tissues

In 1997 Charles Vacanti stunned the world with his “Vacanti Mouse”, a landmark in TE that Vacanti and his team successfully grew an ear on the back of a nude mouse following transplanation of a polymer-human chondrocyte construct (73). This fueled further advancement in TE demonstrating the potential to restore tissues with *ex vivo* fabricated constructs using different types of scaffold materials and living cells. Classically, TE relies on a “Regenerative Trinity” which involves the combination of scaffolds/biomaterials, living cells, and signaling/bioactive factors to engineer tissue constructs (21,22,24) (Figure 2). In the last decade, significant progress has been made in the field of TE and regenerative reconstruction of oral and craniofacial tissues due to the advancement of biomaterial science, TE technology, and the understanding of stem cell biology (22-24). Herein, we focus on describing the potential application of dental MSCs in TE and regeneration of OMF tissues.

DPSCs and stem cells from human exfoliated deciduous teeth (SHED)—Human pulp stem cells include precursor cells isolated from dental pulp tissues of human extracted

permanent teeth (DPSC) and SHED (74,75). As the first type of MSCs isolated from dental tissues (50), substantial progress has been made in understanding their biological properties. Their multipotency and immunomodulatory functions suggest their potential application in TE and regenerative therapy of a wide spectrum of pathological conditions (74,75). In fact, the application of DPSCs and SHEDs alone or in combination with different scaffolds in regeneration of oral and craniofacial tissues has been extensively explored in various rodent and large animal models as well as in some pilot clinical studies (Table 2).

In a rat mandibular ramus critical bone defect model, Zhang *et al.* showed that DPSC-seeded E1001(1k)/ β -TCP scaffolds support the rapid regeneration of osteo-dentin-like mineralized jaw tissue, suggesting a promising new therapy for alveolar jaw bone repair and regeneration (80). Jahanbin *et al.* reported that transplantation SHED mixed with collagen matrix significantly enhanced new bone formation in a maxillary alveolar defect model in Wistar rats (82). Another study by Riccio *et al.* showed that silk fibroin/DPSC constructs exhibited strong regenerative capacity for correcting large cranial defects in rats (81). The potential of DPSC and SHED in cranial and maxillofacial bone regeneration have been further demonstrated in rabbit models (Table 2). Using a mandibular distraction model in New Zealand white rabbits, Alkaisy *et al.* showed that SHED can significantly enhance mandibular distraction osteogenesis (DO) (79). Most recently, Zhang *et al.* showed that transplantation of hDPSC/endothelial cells (HUVEC)-seeded E1001(1k)/ β -TCP scaffolds significantly enhance bone formation in critical-sized alveolar bone defects in an *in vivo* rabbit mandible defect model (77). Gutiérrez-Quintero reported that transplantation of DPSCs seeded with hydroxyapatite matrix and polylactic polyglycolic acid (HA/PLGA) scaffolds also significantly augmented bone regeneration in bilateral mandibular critical-sized defects in rabbits (78). Implantation of DPSCs mixed with biodegradable poly[ethylene glycol]-diacrylate [PEGDA] hydrogels thiol-acrylate hydrogels also facilitated cranial bone regeneration in rabbits (76). Most recently, Ghavimi *et al.* reported that DPSCs mixed with nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles can promote guided bone regeneration (GBR) in the defects created in both sides of the dog's jaw (83).

Critical-sized calvarial bone defect model in rodents is another popularly used model to evaluate the bone regenerative potentials of MSCs. Several studies have demonstrated the regenerative effects of DPSCs and SHEDs alone or in combination with different scaffolds on bone formation in critical-sized calvarial defects in mice (84-88) and rats (89-92). In addition, Wongsupa *et al.* reported that implantation of the bioengineered constructs of DPSCs in poly- ϵ -caprolactone (PCL)-biphasic calcium phosphate (BCP) scaffolds augment new bone formation in rabbit calvarial defects (93). In large animal models of dental implant surgeries, it has also been shown that DPSCs increases new bone formation and vertical bone height in experimental sheep (94) and dog (95) models. Most recently, Talaat *et al.* reported the potential use of DPSCs embedded in nanocellulose-chitosan thermosensitive hydrogel for cartilage regeneration (96).

In addition to the potential application of DPSCs and SHED in reconstruction of hard craniofacial and maxillofacial tissues, their use in reconstruction of soft OMF tissues, such as periodontal defects (97,99) and craniofacial nerves (100-102), has been suggested as well.

For instance, Li *et al.* reported that autologous DPSCs derived from inflammatory dental pulps (DPSC-IPs) with β -TCP promote reconstruction of periodontal defects in minipig (97). Hu *et al.* reported that either direct DPSC injection or implantation of DPSC cell sheet significantly regenerated periodontal bone in swine even though DPSC sheet had more bone regeneration capacity compared with DPSC injection (98). In a pilot clinical studies with two patients with periodontal intrabony defects, the same group reported that DPSCs-IPs generated new bones to repair the periodontal defects 9 months after surgical reconstruction (99). For craniofacial nerve regeneration, implantation of DPSC-sheets and DPSCs infilled in PLGA artificial nerve conduits significantly promoted crush-injured and segmental defect models of rat facial nerves, respectively (100,101). The superior laryngeal nerve (SLN) plays an essential role in swallowing. A recent study showed that systemic administration of SHED-conditioned media (SHED-CM) could promote axonal regeneration and functional recovery of injured SLN (102). Altogether, these compelling findings have elucidated the potential application of DPSCs and SHED in TE and regenerative reconstruction of craniomaxillofacial defects.

PDLSC—Since the initial isolation of PDLSCs (52), a number of studies have extensively investigated their extraordinary biological properties and regenerative potentials. Of particular significance is the application of PDLSCs cell sheets alone or in combination with scaffolds in rodent periodontal defect models (Table 3) (103-106) to regenerate the periodontium, a complex composed of root cementum, alveolar bone, gingiva, and periodontal ligament (PDL) (118). For instance, transplantation of PDLSCs combined with Bio-Gide® collagen membrane or GelFoam significantly increased bone volume and average thickness of bone trabecular bone in a rat periodontal defect model, with enhanced regeneration of cementum-like structure and formation of collagen fiber formation (104,106). Nagata *et al.* reported that directly local application of PDLSC-derived conditioned medium (CM) could also enhance rat periodontal regeneration by reducing TNF- α production thereby suppressing the inflammatory responses (105). Lin *et al.* reported that transplantation of PDLSCs with dental implants can organize periodontal tissues at the site of previously lost teeth in rats (107). In periodontal defect models of large animals, such as canines (108,110) and minipigs (109), transplantation of PDLSC sheets or PDLSCs combined with collagen powder over surgically created periodontal defect sites promote periodontal regeneration even under an inflammatory microenvironment (108). In the advanced periodontitis model in dog, where a circumferential defect involving the alveolar bone, periodontal ligament and cementum was surgically created, autologous PDLSCs showed the best regenerative capacity for these structures as well as peripheral nerve and blood vessel (110). Furthermore, a single-arm and single-institute clinical study has demonstrated the safety and efficacy of autologous PDLSC sheets in 10 cases of patients with periodontitis at 6-months following transplantation, with sustained therapeutic effects for a mean follow-up period of 55 ± 19 months and no serious adverse events observed (111).

In addition to the potent periodontal regenerative properties, preclinical studies using rodents and large animal models have shown that PDLSCs can induce craniofacial bone regeneration in rodent and large animal models (Table 3). In a dog model of bilateral maxillary sinus floor augmentation, Yu *et al.* showed that seeding of PDLSCs or BMMSCs

onto Bio-Oss can promote bone formation and mineralization and maintain the maximum volume of the augmented maxillary sinus (112). Meanwhile, several studies have shown that transplantation of PDLSC CM or various PDLSC-seeded scaffolds can significantly enhance bone repair/regeneration in calvarial defects in mice (113,114), rat (115,116), and rabbit (117). These compelling findings have demonstrated that PDLSCs have potentials in the regeneration/reconstruction of oral maxillofacial tissues, particularly, lost/damaged support tissue in the periodontium complex, including the alveolar bone, periodontal ligament, and cementum (119).

Gingiva and oral mucosa-derived MSCs (GMSCs and OMSCs)—GMSCs represent another population of adult dental stem cells isolated from the lamina propria of gingival tissues (53). Similar to other sources of MSCs, GMSCs possess multipotent differentiation and potent immunomodulatory/anti-inflammatory capacities, making them an easily accessible source of MSCs for TE and regenerative therapy of various craniofacial and noncraniofacial disorders (120,121) (Table 4). Several lines of evidence have shown that transplantation of GMSC-derived CM, exosomes or GMSC-seeded scaffolds can stimulate periodontal repair/regeneration in periodontal defect models in rats (122,123), dogs (124), and minipigs (125). For instance, Yu *et al.* reported that transplanted GMSCs significantly enhanced the regeneration of the damaged periodontal tissue, including the alveolar bone, cementum and periodontal ligament (PDL) in Class III furcation defects of dogs. They found that GMSCs were able to differentiate into osteoblasts, cementoblasts, and PDL fibroblasts *in vivo* (124). These findings indicate that GMSCs represent a novel cell source for periodontal tissue. Fawzy El-Sayed *et al.* reported that GMSCs in conjunction with IL-1Ra-loaded HA-sECM significantly enhance periodontal regeneration in a minipig model (125).

In addition to the periodontal regenerative capacity, several preclinical studies have shown that GMSCs also have the potential to promote craniofacial bone regeneration in rodents (126-129) and minipigs (130). Most recently, a study has shown that GMSCs effectively delivered by a bioinspired adhesive hydrogel with tunable mechanical properties and biodegradability, can aggregate, form hydroxyapatite microparticles, and significantly promote craniofacial bone regeneration in rats (127). In a critical-sized maxillary alveolar defect model in nude rats, combination of predifferentiated osteogenic GMSCs, self-assembling hydrogel PuraMatrix™ (PM), and low doses of BMP2 accelerated alveolar bone regeneration when compared to cells or material alone. Predifferentiated osteogenic GMSCs are GMSCs induced with osteogenic medium resulting in increased expression of osteogenic surface markers such as CD10, CD92, and CD140b (128). An early study showed that implantation of GMSCs seeded on type I collagen gel significantly facilitate repair/regeneration of the mandibular and calvarial defects at 2 months in rats postsurgical reconstruction (129). Most recently, Shi *et al.* reported that treatment with a TGF- β signaling inhibitor, SB431542, increased the osteogenic differentiation potential of GMSCs and transplantation of autologous pig GMSCs pretreated with SB431542 significantly induce bone regeneration in critical-sized maxillofacial bone defects of minipigs (130).

In spite of their bone regenerative potentials, several lines of evidence have shown that transplantation of GMSCs can facilitate oral and craniofacial soft tissue repair/

regeneration, such as palatal wound (70,133), gingival (134), and tongue myomucosal defects (135,136), and facial nerve injuries (137,138). For instance, Li *et al.* recently reported that transplantation of GMSCs from human fetal gingival tissue remarkably promotes repair/regeneration of gingival defects in a rat model (134). Using a critical-sized tongue defect model in rats, Xu (136) and Zhang (135) *et al.* reported that implantation of GMSC-loaded porcine small intestine submucosal extracellular matrix (SIS-ECM) membrane remarkably facilitated regeneration of tongue muscles and taste buds possibly by promoting endogenous muscle stem cell activation and suppressing fibrosis. Recently, Zhang *et al.* reported that implantation of 3D bio-printed scaffold free nerve structures with 3D-spheroids of GMSCs as the only cellular “bio-ink” (137) or implantation of collagen nerve conduits loaded with GMSC-induced NC stem-like cells (138) robustly promote axonal regeneration and functional recovery of transected facial nerves in rats. Altogether, these studies have underscored the potential application of GMSCs in TE and regenerative reconstruction of OMF tissue defects.

Dental follicle progenitor cells (DFPCs)—DFSCs represent a population of stem cells that contributes to the development of the periodontal ligament, cementum, and alveolar bone proper (139). Several preclinical studies have demonstrated the oral and craniofacial regenerative potentials of DFSCs in rodents (140-143) and large animal models (108,141,144) (Table 5). A recent study showed that transplantation of DFSC cell sheets or DFSCs in combination with treated dentin matrix (TDM) induced periodontal-like tissue formation in dogs (141). In a canine periodontal defect model, Guo *et al.* reported that implantation of DFSC cell sheets robustly promoted the complete periodontal regeneration, including periodontal ligament-cementum complex and alveolar bone formation (108). In an early study, Zuolin *et al.* reported that transplantation of DFSC-beta-tricalcium phosphate ceramic (beta-TCP) complex promote the restoration of periodontal defects in beagle dogs (144). In addition, the regenerative potential of DFSCs on bone formation has also been demonstrated in alveolar and cranial bone defect models in rats (141-143). For example, implantation of DFSC-polycaprolactone (PCL) scaffold constructs significantly enhanced bone regeneration in critical-size skull defects in rats (142). In an alveolar bone defect model in rats, Nie *et al.* reported that implantation of bio-implants composed of Ad-BMP9-transfected rat DFSCs and coralline hydroxyapatite (CHA) scaffolds remarkably enhance alveolar bone regeneration (143). These findings have demonstrated the potential application of DFSCs in regenerative reconstruction of OMF tissues.

SCAP—SCAP represent a unique subpopulation of dental stem cells from immature permanent teeth (54) and have been shown to be another type of dental MSCs with potential application in regenerative endodontic procedures and TE/RM in general (149,150) (Table 5). When 3D-printed hydroxyapatite scaffolds containing DPSCs and/or SCAPs were subcutaneously transplanted into immunocompromised mice, vascularized pulp-like tissue as well as mineralized tissue formed at 12-weeks posttransplantation, demonstrating angiogenic and regenerative potential (145). Li *et al.* recently reported that local injection of SCAPs promote periodontal complex regeneration in the swine periodontitis model (147,148). Altogether, these findings support the potential application of SCAPs in regenerative reconstruction of OMF tissues.

Application of dental MSC-EVs in OMF tissue regeneration

MSC-EVs serve a myriad of biological functions and possess immense therapeutic potential (44,48). Accumulating evidence has shown the potential use of dental MSC-derived EVs as cell-free agents in TE and regenerative therapy in the dental and craniofacial reconstruction (151,152) (Figure 2). Administration of CM derived from different types of dental-MSCs displayed potent regenerative/therapeutic potentials in oral and craniofacial defect models. For instance, SHED-CM has been shown to induce rat superior laryngeal nerve (SLN) regeneration (102). PDLSC-CM could stimulate bone regeneration in calvarial defects of mice (114) and periodontal regeneration in rats (105). GMSC-CM and DFSC-CM significantly promote rat periodontal (122) and pulp-dentin (140) regeneration, respectively. Additionally, it has been shown that GMSC-EVs loaded with a poly-(lactide) (3D-PLA) facilitated calvarial bone regeneration in rats (153).

In recent years, surmounting evidence has implicated the regenerative/therapeutic potentials of EVs released by different types of dental-MSCs (Table 5). Swanson *et al.* reported that application of DPSC-EVs with a controlled-release by PLGA and poly(ethylene glycol) (PEG) remarkably increase calvarial bone regeneration in mice (84). DPSC-EVs promote dentin-pulp regeneration following injection into the exposed pulp tissue of rat incisors (154). In a minipig model of pulp injury, Wen *et al.* reported that treatment with DPSC-EVs mixed with treated dentin matrix (TDM) proteins significantly promote pulp-dentin complex repair/regeneration (155). Regarding the regenerative/therapeutic potential of GMSC-EVs in OMF defects, Kou *et al.* showed that local injection of GMSC-EVs significantly facilitated palatal wound healing in mice (70). Most recently, it has been reported that EVs from TNF- α -preconditioned GMSCs displayed potent regenerative/therapeutic potentials in periodontal regeneration of mice (123). In a critical-sized tongue defect model in rats, Zhang *et al.* showed that transplantation of SIS-ECM loaded with GMSC-EVs significantly promoted taste bud regeneration (135). Furthermore, implantation of GMSC-EVs loaded with 3D printing biomaterial, poly(lactide) (3D-PLA), display bone regenerative capacity in calvarial defects in rats (131,132). In a nude mice model, subcutaneous transplantation of BMSCs mixed with SCAP-Exo showed significantly increased ectopic formation of dentine-pulp like structures, suggesting the specific dentinogenetic potential of SCAP-EVs (146). Lastly, Shi *et al.* has recently reported that application of hydrogel loaded with EVs derived from LPS-preconditioned DFSCs remarkably prevented bone loss and engendered new bone formation in experimental rat periodontitis model (156). Taken together, these results demonstrate compelling evidence for the use of CM and/or purified EVs derived from dental-MSCs as alternative cell-free products for TE and regenerative reconstruction of OMF tissue defects.

Challenges of MSC-based regenerative therapies

Despite a favorable safety profile and numerous studies demonstrating its effectiveness in preclinical studies, in general, there has been limited success of application of MSCs and MSC-EVs in humans (41,42). The cause of this translational barrier is due to multiple intrinsic and extrinsic factors that can contribute to the heterogeneity in the potency of MSC products. These factors include differences in donors (e.g., their age, health status, tissue origins), the methods for MSC preparation (e.g., the isolation, *ex vivo* culture/expansion, and storage) and administration (e.g., the route, dosage, frequency, and the carrier/vehicle)

as well as the health/disease status of the recipients (42). In term of MSC-based TE, the difference in the type of biomaterials or scaffolds, TE technologies, small molecules and/growth factors may also significantly affect the potency and clinical outcomes of MSC-based TE products (157). Even though a general safety profile has been well recognized for MSC-based therapy, there are still some related potential risks, side effects or complications, such as acute/immediate responses to MSC administration, infection, thrombotic/embolic (158), and ectopic calcification (159), heterotopic ossification (160), or tumor-like tissue mass formation (161). Therefore, more rigorous studies are warranted to evaluate the therapeutic potency as well as potential short-term and long-term complications related to MSC-based regenerative therapy, including MSC-based reconstruction and rehabilitation of OMF defects.

Summary

Significant progress has been made in TE and MSC-based regenerative therapy across many fields of medicine, including oral & maxillofacial reconstruction and facial cosmetics (22,23). To date, there have been over 1,200 registered and 300 completed clinical trials using MSCs to treat a large spectrum of pathological conditions (<https://www.clinicaltrials.gov/>) (42), including MSCs used in the management of craniofacial injuries or abnormalities (<https://www.clinicaltrials.gov/>). In addition, MSC-derived EVs, a cell-free product, implemented in many preclinical models of diseases, have demonstrated therapeutic capacity in the regeneration of OMF tissues (Table 6). Of note, however, MSCs and MSC-EV products when applied to humans do not show the same therapeutic effect. This is largely attributed to the heterogeneity in the potency and property of MSCs owing to differing intrinsic factors, such as the tissue source and donor characteristics, as well as extrinsic factors, such as methods and technologies involved in tissue harvesting, cell isolation/expansion, TE, and product storage/administration (42). It is thus essential to establish standard operating procedures (SOP) for all the steps in the production of dental MSCs, MSC-EVs, or MSC-based TE constructs with cGMP qualities (15). Generation of MSC-EVs presents additional technical and biological challenges (162,163). Specifically, cell isolation methods significantly affect the purity and yield of EVs (164), while the source and status of cells affect the production and cargo components of MSC-EVs (162,163). To advance the clinical application of MSC-EVs in OMF tissue regeneration and reconstruction, it is critical to experimentally optimize their production in future studies.

Acknowledgments

Funding: This work was supported by the National Institute of Dental and Craniofacial Research (NIH/NIDCR) No. R21DE029926-01 (A. Le), the Schoenleber funding support (A. Le and Q. Zhang), the Project Funding from Center for Human Appearance (CHA) at UPenn (Q. Zhang), OsteoScience Foundation-Peter Geistlich Research Awards (R. Shanti, Q. Zhang), Oral & Maxillofacial Surgery Foundation (OMSF)-Research Support Grant (R. Shanti, Q. Zhang), OsteoScience Foundation-Resident Research Awards (P. He).

Conflicts of Interest:

All authors have completed the ICMJE uniform disclosure form (available at <https://fomm.amegroups.com/article/view/10.21037/fomm-21-10/coif>). The series “Clinical Outcomes and Innovations in Oral and Maxillofacial Surgery” was commissioned by the editorial office without any funding or sponsorship. This work was supported by the National Institute of Dental and Craniofacial Research (NIH/NIDCR) R21DE029926-01 (A. Le), the Schoenleber funding support (A. Le and Q. Zhang), the Project Funding from Center for Human Appearance

(CHA) at UPenn (Q. Zhang), OsteoScience Foundation-Peter Geistlich Research Awards (R. Shanti, Q. Zhang), Oral & Maxillofacial Surgery Foundation (OMSF)-Research Support Grant (R. Shanti, Q. Zhang), OsteoScience Foundation-Resident Research Awards (P. He). The authors have no other conflicts of interest to declare.

References

1. Markiewicz MR, Gelesko S, Bell RB. Zygoma reconstruction. *Oral Maxillofac Surg Clin North Am* 2013;25:167–201. [PubMed: 23642668]
2. Lenox ND, Kim DD. Maxillary reconstruction. *Oral Maxillofac Surg Clin North Am* 2013;25:215–22. [PubMed: 23642669]
3. Fernandes RP, Yetzer JG. Reconstruction of acquired oromandibular defects. *Oral Maxillofac Surg Clin North Am* 2013;25:241–9. [PubMed: 23642671]
4. Vega LG, González-García R, Louis PJ. Reconstruction of acquired temporomandibular joint defects. *Oral Maxillofac Surg Clin North Am* 2013;25:251–69. [PubMed: 23642672]
5. Twigg SR, Wilkie AO. New insights into craniofacial malformations. *Hum Mol Genet* 2015;24:R50–9. [PubMed: 26085576]
6. Hunter C, Januszyk M, Wan DC, et al. Systematic Reviews in Craniofacial Trauma-Strengths and Weaknesses. *Ann Plast Surg* 2016;77:363–8. [PubMed: 26418794]
7. Khokha MK, Liu KJ, Wallingford JB. Challenges and opportunities at the interface of birth defects, human genetics and developmental biology. *Development* 2020;147:dev197871. [PubMed: 33168578]
8. Nyberg EL, Farris AL, Hung BP, et al. 3D-Printing Technologies for Craniofacial Rehabilitation, Reconstruction, and Regeneration. *Ann Biomed Eng* 2017;45:45–57. [PubMed: 27295184]
9. Zhang W, Yelick PC. Craniofacial Tissue Engineering. *Cold Spring Harb Perspect Med* 2018;8:a025775. [PubMed: 28348178]
10. Shanti RM, O'Malley BW Jr. Surgical Management of Oral Cancer. *Dent Clin North Am* 2018;62:77–86. [PubMed: 29126495]
11. Valdez JA, Brennan MT. Impact of Oral Cancer on Quality of Life. *Dent Clin North Am* 2018;62:143–54. [PubMed: 29126491]
12. Streubel SO, Mirsky DM. Craniomaxillofacial Trauma. *Facial Plast Surg Clin North Am* 2016;24:605–17. [PubMed: 27712825]
13. Petrovic I, Rosen EB, Matros E, et al. Oral rehabilitation of the cancer patient: A formidable challenge. *J Surg Oncol* 2018;117:1729–35. [PubMed: 29723421]
14. Barclay CW, Foster EC, Taylor CL. Restorative aspects of oral cancer reconstruction. *Br Dent J* 2018;225:848–54. [PubMed: 30412540]
15. Zhang QZ, Chen C, Chang MB, et al. Oral Rehabilitation of Patients Sustaining Orofacial Injuries: The UPenn Initiative. *Adv Dent Res* 2019;30:50–6. [PubMed: 31633385]
16. Kumar BP, Venkatesh V, Kumar KA, et al. Mandibular Reconstruction: Overview. *J Maxillofac Oral Surg* 2016;15:425–41. [PubMed: 27833334]
17. Minatel L, Marcela de Luna Gomes J, Aparecido Araújo Lemos C, et al. Influence of vomer flap on craniofacial growth in patients with cleft lip and palate: A systematic review. *J Craniomaxillofac Surg* 2019;47:902–8. [PubMed: 30935851]
18. van Gijn DR, D'Souza J, King W, et al. Free Flap Head and Neck Reconstruction with an Emphasis on Postoperative Care. *Facial Plast Surg* 2018;34:597–604. [PubMed: 30593075]
19. Boehm KS, Al-Taha M, Morzycki A, et al. Donor Site Morbidities of Iliac Crest Bone Graft in Craniofacial Surgery: A Systematic Review. *Ann Plast Surg* 2019;83:352–8. [PubMed: 30562201]
20. Broyles JM, Abt NB, Shridharani SM, et al. The fusion of craniofacial reconstruction and microsurgery: a functional and aesthetic approach. *Plast Reconstr Surg* 2014;134:760–9. [PubMed: 25357035]
21. Armstrong JPK, Keane TJ, Roques AC, et al. A blueprint for translational regenerative medicine. *Sci Transl Med* 2020;12:eaaz2253. [PubMed: 33268507]
22. Borrelli MR, Hu MS, Longaker MT, et al. Tissue Engineering and Regenerative Medicine in Craniofacial Reconstruction and Facial Aesthetics. *J Craniofac Surg* 2020;31:15–27. [PubMed: 31369496]

23. Pourlak T, Pourlak T, Ghodrati M, et al. Usage of stem cells in oral and maxillofacial region. *J Stomatol Oral Maxillofac Surg* 2020. [Epub ahead of print]. doi: 10.1016/j.jormas.2020.10.003.
24. Matichescu A, Ardelean LC, Rusu LC, et al. Advanced Biomaterials and Techniques for Oral Tissue Engineering and Regeneration-A Review. *Materials (Basel)* 2020;13:5303.
25. Shanti RM, Li WJ, Nesti LJ, et al. Adult mesenchymal stem cells: biological properties, characteristics, and applications in maxillofacial surgery. *J Oral Maxillofac Surg* 2007;65:1640–7. [PubMed: 17656295]
26. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet* 1970;3:393–403. [PubMed: 5523063]
27. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. *Blood* 1980;56:289–301. [PubMed: 6994839]
28. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–7. [PubMed: 16923606]
29. Aust L, Devlin B, Foster SJ, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. *Cytotherapy* 2004;6:7–14. [PubMed: 14985162]
30. Klein D. Lung Multipotent Stem Cells of Mesenchymal Nature: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy. *Antioxid Redox Signal* 2021;35:204–16. [PubMed: 33167666]
31. Yates CC, Rodrigues M, Nuschke A, et al. Multipotent stromal cells/mesenchymal stem cells and fibroblasts combine to minimize skin hypertrophic scarring. *Stem Cell Res Ther* 2017;8:193. [PubMed: 28874184]
32. He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. *Stem Cells* 2007;25:69–77. [PubMed: 16973831]
33. Fan J, Varshney RR, Ren L, et al. Synovium-derived mesenchymal stem cells: a new cell source for musculoskeletal regeneration. *Tissue Eng Part B Rev* 2009;15:75–86. [PubMed: 19196118]
34. amernik K, Marc J, Zupan J. Human Skeletal Muscle-Derived Mesenchymal Stem/Stromal Cell Isolation and Growth Kinetics Analysis. *Methods Mol Biol* 2019;2045:119–29. [PubMed: 30499023]
35. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells* 2004;22:1338–45. [PubMed: 15579651]
36. Xie Q, Liu R, Jiang J, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? *Stem Cell Res Ther* 2020;11:519. [PubMed: 33261658]
37. Gan L, Liu Y, Cui D, et al. Dental Tissue-Derived Human Mesenchymal Stem Cells and Their Potential in Therapeutic Application. *Stem Cells Int* 2020;2020:8864572. [PubMed: 32952572]
38. Tatullo M, Marrelli M, Paduano F. The regenerative medicine in oral and maxillofacial surgery: the most important innovations in the clinical application of mesenchymal stem cells. *Int J Med Sci* 2015;12:72–7. [PubMed: 25552921]
39. El Agha E, Kramann R, Schneider RK, et al. Mesenchymal Stem Cells in Fibrotic Disease. *Cell Stem Cell* 2017;21:166–77. [PubMed: 28777943]
40. Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration: from mechanism to therapy. *Nat Med* 2014;20:857–69. [PubMed: 25100531]
41. Martin I, Galipeau J, Kessler C, et al. Challenges for mesenchymal stromal cell therapies. *Sci Transl Med* 2019;11:eaat2189. [PubMed: 30787168]
42. Levy O, Kuai R, Siren EMJ, et al. Shattering barriers toward clinically meaningful MSC therapies. *Sci Adv* 2020;6:eaba6884. [PubMed: 32832666]
43. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. *Nat Rev Nephrol* 2018;14:493–507. [PubMed: 29895977]
44. Fu Y, Karbaat L, Wu L, et al. Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration. *Tissue Eng Part B Rev* 2017;23:515–28. [PubMed: 28490258]

45. Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. *Cytotherapy* 2019;21:1019–24. [PubMed: 31526643]
46. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science* 2020;367:eaau6977. [PubMed: 32029601]
47. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends Cell Biol* 2015;25:364–72. [PubMed: 25683921]
48. Tsiapalis D, O'Driscoll L. Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications. *Cells* 2020;9:991.
49. Cooper LF, Ravindran S, Huang CC, et al. A Role for Exosomes in Craniofacial Tissue Engineering and Regeneration. *Front Physiol* 2019;10:1569. [PubMed: 32009978]
50. Gronthos S, Mankani M, Brahimi J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci U S A* 2000;97:13625–30. [PubMed: 11087820]
51. Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci U S A* 2003;100:5807–12. [PubMed: 12716973]
52. Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004;364:149–55. [PubMed: 15246727]
53. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. *J Immunol* 2009;183:7787–98. [PubMed: 19923445]
54. Sonoyama W, Liu Y, Yamaza T, et al. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. *J Endod* 2008;34:166–71. [PubMed: 18215674]
55. Yao S, Pan F, Prpic V, et al. Differentiation of stem cells in the dental follicle. *J Dent Res* 2008;87:767–71. [PubMed: 18650550]
56. Guven EP, Yalvac ME, Sahin F, et al. Effect of dental materials calcium hydroxide-containing cement, mineral trioxide aggregate, and enamel matrix derivative on proliferation and differentiation of human tooth germ stem cells. *J Endod* 2011;37:650–6. [PubMed: 21496665]
57. Andrukhov O, Behm C, Blufstein A, et al. Immunomodulatory properties of dental tissue-derived mesenchymal stem cells: Implication in disease and tissue regeneration. *World J Stem Cells* 2019;11:604–17. [PubMed: 31616538]
58. Liu J, Yu F, Sun Y, et al. Concise reviews: Characteristics and potential applications of human dental tissue-derived mesenchymal stem cells. *Stem Cells* 2015;33:627–38. [PubMed: 25447379]
59. Perera SN, Kerosuo L. On the road again: Establishment and maintenance of stemness in the neural crest from embryo to adulthood. *Stem Cells* 2021;39:7–25. [PubMed: 33017496]
60. Etchevers HC, Dupin E, Le Douarin NM. The diverse neural crest: from embryology to human pathology. *Development* 2019;146:dev169821. [PubMed: 30858200]
61. Solis-Castro OO, Boissonade FM, Rivolta MN. Establishment and neural differentiation of neural crest-derived stem cells from human dental pulp in serum-free conditions. *Stem Cells Transl Med* 2020;9:1462–76. [PubMed: 32633468]
62. Marynka-Kalmani K, Treves S, Yafee M, et al. The lamina propria of adult human oral mucosa harbors a novel stem cell population. *Stem Cells* 2010;28:984–95. [PubMed: 20474080]
63. Abe S, Yamaguchi S, Sato Y, et al. Sphere-Derived Multipotent Progenitor Cells Obtained From Human Oral Mucosa Are Enriched in Neural Crest Cells. *Stem Cells Transl Med* 2016;5:117–28. [PubMed: 26582909]
64. Fournier BP, Loison-Robert LS, Ferré FC, et al. Characterisation of human gingival neural crest-derived stem cells in monolayer and neurosphere cultures. *Eur Cell Mater* 2016;31:40–58. [PubMed: 26728498]
65. Davies LC, Locke M, Webb RD, et al. A multipotent neural crest-derived progenitor cell population is resident within the oral mucosa lamina propria. *Stem Cells Dev* 2010;19:819–30. [PubMed: 20132052]
66. Gösau M, Gotz W, Felthaus O, et al. Comparison of the differentiation potential of neural crest derived progenitor cells from apical papilla (dNC-PCs) and stem cells from exfoliated deciduous teeth (SHED) into mineralising cells. *Arch Oral Biol* 2013;58:699–706. [PubMed: 23261253]

67. Lima RL, Holanda-Afonso RC, Moura-Neto V, et al. Human dental follicle cells express embryonic, mesenchymal and neural stem cells markers. *Arch Oral Biol* 2017;73:121–8. [PubMed: 27764680]
68. Pisciotta A, Bertoni L, Vallarola A, et al. Neural crest derived stem cells from dental pulp and tooth-associated stem cells for peripheral nerve regeneration. *Neural Regen Res* 2020;15:373–81. [PubMed: 31571644]
69. Xu X, Chen C, Akiyama K, et al. Gingivae contain neuralcrest- and mesoderm-derived mesenchymal stem cells. *J Dent Res* 2013;92:825–32. [PubMed: 23867762]
70. Kou X, Xu X, Chen C, et al. The Fas/Fap-1/Cav-1 complex regulates IL-1RA secretion in mesenchymal stem cells to accelerate wound healing. *Sci Transl Med* 2018;10:eaa8524. [PubMed: 29540618]
71. Shi HZ, Zeng JC, Shi SH, et al. Extracellular Vesicles of GMSCs Alleviate Aging-Related Cell Senescence. *J Dent Res* 2021;100:283–92. [PubMed: 33073684]
72. Zhou H, Li X, Yin Y, et al. The proangiogenic effects of extracellular vesicles secreted by dental pulp stem cells derived from periodontally compromised teeth. *Stem Cell Res Ther* 2020;11:110. [PubMed: 32143712]
73. Cao Y, Vacanti JP, Paige KT, et al. Transplantation of chondrocytes utilizing a polymer-cell construct to produce tissue-engineered cartilage in the shape of a human ear. *Plast Reconstr Surg* 1997;100:297–302; discussion 303-4. [PubMed: 9252594]
74. Sui B, Wu D, Xiang L, et al. Dental Pulp Stem Cells: From Discovery to Clinical Application. *J Endod* 2020;46:S46–55. [PubMed: 32950195]
75. Shi X, Mao J, Liu Y. Pulp stem cells derived from human permanent and deciduous teeth: Biological characteristics and therapeutic applications. *Stem Cells Transl Med* 2020;9:445–64. [PubMed: 31943813]
76. Aghali A, Arman HE. Photoencapsulated-mesenchymal stromal cells in biodegradable thiol-acrylate hydrogels enhance regeneration of craniofacial bone tissue defects. *Regen Med* 2020;15:2115–27. [PubMed: 33211632]
77. Zhang W, Saxena S, Fakhrzadeh A, et al. Use of Human Dental Pulp and Endothelial Cell Seeded Tyrosine-Derived Polycarbonate Scaffolds for Robust in vivo Alveolar Jaw Bone Regeneration. *Front Bioeng Biotechnol* 2020;8:796. [PubMed: 32766225]
78. Gutiérrez-Quintero JG, Durán Riveros JY, Martínez Valbuena CA, et al. Critical-sized mandibular defect reconstruction using human dental pulp stem cells in a xenograft model-clinical, radiological, and histological evaluation. *Oral Maxillofac Surg* 2020;24:485–93. [PubMed: 32651701]
79. Alkai A, Ismail AR, Mutum SS, et al. Transplantation of human dental pulp stem cells: enhance bone consolidation in mandibular distraction osteogenesis. *J Oral Maxillofac Surg* 2013;71:1758 e1–13. [PubMed: 24040948]
80. Zhang W, Zhang Z, Chen S, et al. Mandibular Jaw Bone Regeneration Using Human Dental Cell-Seeded Tyrosine-Derived Polycarbonate Scaffolds. *Tissue Eng Part A* 2016;22:985–93. [PubMed: 27369635]
81. Riccio M, Maraldi T, Pisciotta A, et al. Fibroin scaffold repairs critical-size bone defects in vivo supported by human amniotic fluid and dental pulp stem cells. *Tissue Eng Part A* 2012;18:1006–13. [PubMed: 22166080]
82. Jahanbin A, Rashed R, Alamdari DH, et al. Success of Maxillary Alveolar Defect Repair in Rats Using Osteoblast-Differentiated Human Deciduous Dental Pulp Stem Cells. *J Oral Maxillofac Surg* 2016;74:829.e1–9. [PubMed: 26763080]
83. Ghavimi MA, Bani Shahabadi A, Jarolmasjed S, et al. Nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles for guided bone regeneration. *Sci Rep* 2020;10:18200. [PubMed: 33097790]
84. Swanson WB, Zhang Z, Xiu K, et al. Scaffolds with controlled release of pro-mineralization exosomes to promote craniofacial bone healing without cell transplantation. *Acta Biomater* 2020;118:215–32. [PubMed: 33065285]

85. Fujii Y, Kawase-Koga Y, Hojo H, et al. Bone regeneration by human dental pulp stem cells using a helioxanthin derivative and cell-sheet technology. *Stem Cell Res Ther* 2018;9:24. [PubMed: 29391049]
86. Collignon AM, Castillo-Dali G, Gomez E, et al. Mouse Wnt1-CRE-RosaTomato Dental Pulp Stem Cells Directly Contribute to the Calvarial Bone Regeneration Process. *Stem Cells* 2019;37:701–11. [PubMed: 30674073]
87. Novais A, Lesieur J, Sadoine J, et al. Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects. *Stem Cells Transl Med* 2019;8:844–57. [PubMed: 31016898]
88. Nakajima K, Kunimatsu R, Ando K, et al. Comparison of the bone regeneration ability between stem cells from human exfoliated deciduous teeth, human dental pulp stem cells and human bone marrow mesenchymal stem cells. *Biochem Biophys Res Commun* 2018;497:876–82. [PubMed: 29477844]
89. Annibali S, Bellavia D, Ottolenghi L, et al. Micro-CT and PET analysis of bone regeneration induced by biodegradable scaffolds as carriers for dental pulp stem cells in a rat model of calvarial "critical size" defect: Preliminary data. *J Biomed Mater Res B Appl Biomater* 2014;102:815–25. [PubMed: 24142538]
90. Petridis X, Diamanti E, Trigas GCh, et al. Bone regeneration in critical-size calvarial defects using human dental pulp cells in an extracellular matrix-based scaffold. *J Craniomaxillofac Surg* 2015;43:483–90. [PubMed: 25753474]
91. Asutay F, Polat S, Gül M, et al. The effects of dental pulp stem cells on bone regeneration in rat calvarial defect model: micro-computed tomography and histomorphometric analysis. *Arch Oral Biol* 2015;60:1729–35. [PubMed: 26433189]
92. Chamieh F, Collignon AM, Coyac BR, et al. Accelerated craniofacial bone regeneration through dense collagen gel scaffolds seeded with dental pulp stem cells. *Sci Rep* 2016;6:38814. [PubMed: 27934940]
93. Wongsupa N, Nuntanaranont T, Kamolmattayakul S, et al. Assessment of bone regeneration of a tissue-engineered bone complex using human dental pulp stem cells/poly(ϵ -caprolactone)-biphasic calcium phosphate scaffold constructs in rabbit calvarial defects. *J Mater Sci Mater Med* 2017;28:77. [PubMed: 28386853]
94. Çolpak HA, Gönen ZB, Özdamar S, et al. Vertical ridge augmentation using guided bone regeneration procedure and dental pulp derived mesenchymal stem cells with simultaneous dental implant placement: A histologic study in a sheep model. *J Stomatol Oral Maxillofac Surg* 2019;120:216–23. [PubMed: 30579853]
95. Ito K, Yamada Y, Nakamura S, et al. Osteogenic potential of effective bone engineering using dental pulp stem cells, bone marrow stem cells, and periosteal cells for osseointegration of dental implants. *Int J Oral Maxillofac Implants* 2011;26:947–54. [PubMed: 22010075]
96. Talaat W, Aryal Ac S, Al Kawas S, et al. Nanoscale Thermosensitive Hydrogel Scaffolds Promote the Chondrogenic Differentiation of Dental Pulp Stem and Progenitor Cells: A Minimally Invasive Approach for Cartilage Regeneration. *Int J Nanomedicine* 2020;15:7775–89. [PubMed: 33116500]
97. Li Y, Nan X, Zhong TY, et al. Treatment of Periodontal Bone Defects with Stem Cells from Inflammatory Dental Pulp Tissues in Miniature Swine. *Tissue Eng Regen Med* 2019;16:191–200. [PubMed: 30989045]
98. Hu J, Cao Y, Xie Y, et al. Periodontal regeneration in swine after cell injection and cell sheet transplantation of human dental pulp stem cells following good manufacturing practice. *Stem Cell Res Ther* 2016;7:130. [PubMed: 27613503]
99. Li Y, Zhao S, Nan X, et al. Repair of human periodontal bone defects by autologous grafting stem cells derived from inflammatory dental pulp tissues. *Stem Cell Res Ther* 2016;7:141. [PubMed: 27655627]
100. Ahmed MN, Shi D, Dailey MT, et al. Dental Pulp Cell Sheets Enhance Facial Nerve Regeneration via Local Neurotrophic Factor Delivery. *Tissue Eng Part A* 2020. [Epub ahead of print]. doi: 10.1089/ten.TEA.2020.0265.

101. Sasaki R, Aoki S, Yamato M, et al. PLGA artificial nerve conduits with dental pulp cells promote facial nerve regeneration. *J Tissue Eng Regen Med* 2011;5:823–30. [PubMed: 22002926]
102. Tsuruta T, Sakai K, Watanabe J, et al. Dental pulp-derived stem cell conditioned medium to regenerate peripheral nerves in a novel animal model of dysphagia. *PLoS One* 2018;13:e0208938. [PubMed: 30533035]
103. Raju R, Oshima M, Inoue M, et al. Three-dimensional periodontal tissue regeneration using a bone-ligament complex cell sheet. *Sci Rep* 2020;10:1656. [PubMed: 32015383]
104. Liu J, Chen B, Bao J, et al. Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration. *Stem Cell Res Ther* 2019;10:320. [PubMed: 31730019]
105. Nagata M, Iwasaki K, Akazawa K, et al. Conditioned Medium from Periodontal Ligament Stem Cells Enhances Periodontal Regeneration. *Tissue Eng Part A* 2017;23:367–77. [PubMed: 28027709]
106. Han J, Menicanin D, Marino V, et al. Assessment of the regenerative potential of allogeneic periodontal ligament stem cells in a rodent periodontal defect model. *J Periodontal Res* 2014;49:333–45. [PubMed: 23841948]
107. Lin Y, Gallucci GO, Buser D, et al. Bioengineered periodontal tissue formed on titanium dental implants. *J Dent Res* 2011;90:251–6. [PubMed: 21149858]
108. Guo S, Kang J, Ji B, et al. Periodontal-Derived Mesenchymal Cell Sheets Promote Periodontal Regeneration in Inflammatory Microenvironment. *Tissue Eng Part A* 2017;23:585–96. [PubMed: 28437177]
109. Basan T, Welly D, Kriebel K, et al. Enhanced periodontal regeneration using collagen, stem cells or growth factors. *Front Biosci (Schol Ed)* 2017;9:180–93. [PubMed: 27814584]
110. Park JY, Jeon SH, Choung PH. Efficacy of periodontal stem cell transplantation in the treatment of advanced periodontitis. *Cell Transplant* 2011;20:271–85. [PubMed: 20719084]
111. Iwata T, Yamato M, Washio K, et al. Periodontal regeneration with autologous periodontal ligament-derived cell sheets - A safety and efficacy study in ten patients. *Regen Ther* 2018;9:38–44. [PubMed: 30525074]
112. Yu BH, Zhou Q, Wang ZL. Comparison of tissue-engineered bone from different stem cell sources for maxillary sinus floor augmentation: a study in a canine model. *J Oral Maxillofac Surg* 2014;72:1084–92. [PubMed: 24576438]
113. Moshaverinia A, Chen C, Xu X, et al. Bone regeneration potential of stem cells derived from periodontal ligament or gingival tissue sources encapsulated in RGD-modified alginate scaffold. *Tissue Eng Part A* 2014;20:611–21. [PubMed: 24070211]
114. Ogisu K, Fujio M, Tsuchiya S, et al. Conditioned media from mesenchymal stromal cells and periodontal ligament fibroblasts under cyclic stretch stimulation promote bone healing in mouse calvarial defects. *Cytotherapy* 2020;22:543–51. [PubMed: 32798177]
115. Tour G, Wendel M, Moll G, et al. Bone repair using periodontal ligament progenitor cell-seeded constructs. *J Dent Res* 2012;91:789–94. [PubMed: 22736447]
116. Ge S, Zhao N, Wang L, et al. Bone repair by periodontal ligament stem cellseeded nanohydroxyapatite-chitosan scaffold. *Int J Nanomedicine* 2012;7:5405–14. [PubMed: 23091383]
117. Kadkhoda Z, Safarpour A, Azmoodeh F, et al. Histopathological Comparison between Bone Marrow- and Periodontium-derived Stem Cells for Bone Regeneration in Rabbit Calvaria. *Int J Organ Transplant Med* 2016;7:9–18. [PubMed: 26889369]
118. Tomokiyo A, Wada N, Maeda H. Periodontal Ligament Stem Cells: Regenerative Potency in Periodontium. *Stem Cells Dev* 2019;28:974–85. [PubMed: 31215350]
119. Xu XY, Li X, Wang J, et al. Concise Review: Periodontal Tissue Regeneration Using Stem Cells: Strategies and Translational Considerations. *Stem Cells Transl Med* 2019;8:392–403. [PubMed: 30585445]
120. Zhang QZ, Nguyen AL, Yu WH, et al. Human oral mucosa and gingiva: a unique reservoir for mesenchymal stem cells. *J Dent Res* 2012;91:1011–8. [PubMed: 22988012]
121. Gao X, Cao Z. Gingiva-derived Mesenchymal Stem Cells and Their Potential Applications in Oral and Maxillofacial Diseases. *Curr Stem Cell Res Ther* 2020;15:43–53. [PubMed: 31702517]

122. Qiu J, Wang X, Zhou H, et al. Enhancement of periodontal tissue regeneration by conditioned media from gingiva-derived or periodontal ligament-derived mesenchymal stem cells: a comparative study in rats. *Stem Cell Res Ther* 2020;11:42. [PubMed: 32014015]
123. Nakao Y, Fukuda T, Zhang Q, et al. Exosomes from TNF- α -treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss. *Acta Biomater* 2021;122:306–24. [PubMed: 33359765]
124. Yu X, Ge S, Chen S, et al. Human gingiva-derived mesenchymal stromal cells contribute to periodontal regeneration in beagle dogs. *Cells Tissues Organs* 2013;198:428–37. [PubMed: 24777155]
125. Fawzy El-Sayed KM, Mekhemar MK, Beck-Broichsitter BE, et al. Periodontal regeneration employing gingival margin-derived stem/progenitor cells in conjunction with IL-1ra-hydrogel synthetic extracellular matrix. *J Clin Periodontol* 2015;42:448–57. [PubMed: 25875208]
126. Xu QC, Wang ZG, Ji QX, et al. Systemically transplanted human gingiva-derived mesenchymal stem cells contributing to bone tissue regeneration. *Int J Clin Exp Pathol* 2014;7:4922–9. [PubMed: 25197363]
127. Hasani-Sadrabadi MM, Sarrion P, Pouraghaei S, et al. An engineered cell-laden adhesive hydrogel promotes craniofacial bone tissue regeneration in rats. *Sci Transl Med* 2020;12:eaay6853. [PubMed: 32161103]
128. Kandalam U, Kawai T, Ravindran G, et al. Predifferentiated Gingival Stem Cell-Induced Bone Regeneration in Rat Alveolar Bone Defect Model. *Tissue Eng Part A* 2021;27:424–36. [PubMed: 32729362]
129. Wang F, Yu M, Yan X, et al. Gingiva-derived mesenchymal stem cell-mediated therapeutic approach for bone tissue regeneration. *Stem Cells Dev* 2011;20:2093–102. [PubMed: 21361847]
130. Shi A, Heinayati A, Bao D, et al. Small molecule inhibitor of TGF- β signaling enables robust osteogenesis of autologous GMSCs to successfully repair minipig severe maxillofacial bone defects. *Stem Cell Res Ther* 2019;10:172. [PubMed: 31196174]
131. Pizzicannella J, Diomede F, Gugliandolo A, et al. 3D Printing PLA/Gingival Stem Cells/ EVs Upregulate miR-2861 and -210 during Osteoangiogenesis Commitment. *Int J Mol Sci* 2019;20:3256.
132. Diomede F, Gugliandolo A, Cardelli P, et al. Three-dimensional printed PLA scaffold and human gingival stem cell-derived extracellular vesicles: a new tool for bone defect repair. *Stem Cell Res Ther* 2018;9:104. [PubMed: 29653587]
133. Su Y, Chen C, Guo L, et al. Ecological Balance of Oral Microbiota Is Required to Maintain Oral Mesenchymal Stem Cell Homeostasis. *Stem Cells* 2018;36:551–61. [PubMed: 29266799]
134. Li J, Xu SQ, Zhang K, et al. Treatment of gingival defects with gingival mesenchymal stem cells derived from human fetal gingival tissue in a rat model. *Stem Cell Res Ther* 2018;9:27. [PubMed: 29402326]
135. Zhang Y, Shi S, Xu Q, et al. SIS-ECM Laden with GMSC-Derived Exosomes Promote Taste Bud Regeneration. *J Dent Res* 2019;98:225–33. [PubMed: 30335555]
136. Xu Q, Shanti RM, Zhang Q, et al. A Gingiva-Derived Mesenchymal Stem Cell-Laden Porcine Small Intestinal Submucosa Extracellular Matrix Construct Promotes Myomucosal Regeneration of the Tongue. *Tissue Eng Part A* 2017;23:301–12. [PubMed: 27923325]
137. Zhang Q, Nguyen PD, Shi S, et al. 3D bio-printed scaffold-free nerve constructs with human gingiva-derived mesenchymal stem cells promote rat facial nerve regeneration. *Sci Rep* 2018;8:6634. [PubMed: 29700345]
138. Zhang Q, Nguyen PD, Shi S, et al. Neural Crest Stem-Like Cells Non-genetically Induced from Human Gingiva-Derived Mesenchymal Stem Cells Promote Facial Nerve Regeneration in Rats. *Mol Neurobiol* 2018;55:6965–83. [PubMed: 29372546]
139. Zhang J, Ding H, Liu X, et al. Dental Follicle Stem Cells: Tissue Engineering and Immunomodulation. *Stem Cells Dev* 2019;28:986–94. [PubMed: 30968740]
140. Hong H, Chen X, Li K, et al. Dental follicle stem cells rescue the regenerative capacity of inflamed rat dental pulp through a paracrine pathway. *Stem Cell Res Ther* 2020;11:333. [PubMed: 32746910]

141. Yang H, Li J, Hu Y, et al. Treated dentin matrix particles combined with dental follicle cell sheet stimulate periodontal regeneration. *Dent Mater* 2019;35:1238–53. [PubMed: 31201017]
142. Rezai-Rad M, Bova JF, Orooji M, et al. Evaluation of bone regeneration potential of dental follicle stem cells for treatment of craniofacial defects. *Cytotherapy* 2015;17:1572–81. [PubMed: 26342992]
143. Nie L, Yang X, Duan L, et al. The healing of alveolar bone defects with novel bio-implants composed of Ad-BMP9-transfected rDFCs and CHA scaffolds. *Sci Rep* 2017;7:6373. [PubMed: 28743897]
144. Zuolin J, Hong Q, Jiali T. Dental follicle cells combined with beta-tricalcium phosphate ceramic: a novel available therapeutic strategy to restore periodontal defects. *Med Hypotheses* 2010;75:669–70. [PubMed: 20800363]
145. Hilkens P, Bronckaers A, Ratajczak J, et al. The Angiogenic Potential of DPSCs and SCAPs in an In Vivo Model of Dental Pulp Regeneration. *Stem Cells Int* 2017;2017:2582080. [PubMed: 29018483]
146. Zhuang X, Ji L, Jiang H, et al. Exosomes Derived from Stem Cells from the Apical Papilla Promote Dentine-Pulp Complex Regeneration by Inducing Specific Dentinogenesis. *Stem Cells Int* 2020;2020:5816723. [PubMed: 32565828]
147. Li G, Han N, Zhang X, et al. Local Injection of Allogeneic Stem Cells from Apical Papilla Enhanced Periodontal Tissue Regeneration in Minipig Model of Periodontitis. *Biomed Res Int* 2018;2018:3960798. [PubMed: 30112386]
148. Li G, Han N, Yang H, et al. SFRP2 promotes stem cells from apical papilla-mediated periodontal tissue regeneration in miniature pig. *J Oral Rehabil* 2020;47 Suppl 1:12–8. [PubMed: 31469431]
149. Nada OA, El Backly RM. Stem Cells From the Apical Papilla (SCAP) as a Tool for Endogenous Tissue Regeneration. *Front Bioeng Biotechnol* 2018;6:103. [PubMed: 30087893]
150. Pelissari C, Paris AFC, Mantesso A, et al. Apical Papilla Cells Are Capable of Forming a Pulp-like Tissue with Odontoblast-like Cells without the Use of Exogenous Growth Factors. *J Endod* 2018;44:1671–6. [PubMed: 30409448]
151. Xing X, Han S, Li Z, et al. Emerging role of exosomes in craniofacial and dental applications. *Theranostics* 2020;10:8648–64. [PubMed: 32754269]
152. Lv L, Sheng C, Zhou Y. Extracellular vesicles as a novel therapeutic tool for cell-free regenerative medicine in oral rehabilitation. *J Oral Rehabil* 2020;47 Suppl 1:29–54. [PubMed: 31520537]
153. Diomedea F, Gugliandolo A, Scionti D, et al. Biotherapeutic Effect of Gingival Stem Cells Conditioned Medium in Bone Tissue Restoration. *Int J Mol Sci* 2018;19:329.
154. Zheng J, Kong Y, Hu X, et al. MicroRNA-enriched small extracellular vesicles possess odonto-immunomodulatory properties for modulating the immune response of macrophages and promoting odontogenesis. *Stem Cell Res Ther* 2020;11:517. [PubMed: 33256846]
155. Wen B, Huang Y, Qiu T, et al. Reparative Dentin Formation by Dentin Matrix Proteins and Small Extracellular Vesicles. *J Endod* 2021;47:253–62. [PubMed: 33245976]
156. Shi W, Guo S, Liu L, et al. Small Extracellular Vesicles from Lipopolysaccharide-Preconditioned Dental Follicle Cells Promote Periodontal Regeneration in an Inflammatory Microenvironment. *ACS Biomater Sci Eng* 2020;6:5797–810. [PubMed: 33320548]
157. Gomes ME, Rodrigues MT, Domingues RMA, et al. Tissue Engineering and Regenerative Medicine: New Trends and Directions-A Year in Review. *Tissue Eng Part B Rev* 2017;23:211–24. [PubMed: 28457175]
158. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. *EClinicalMedicine* 2020;19:100249. [PubMed: 31989101]
159. Liao J, Chen X, Li Y, et al. Transfer of bone-marrow-derived mesenchymal stem cells influences vascular remodeling and calcification after balloon injury in hyperlipidemic rats. *J Biomed Biotechnol* 2012;2012:165296. [PubMed: 22665980]
160. Agarwal S, Loder S, Cholok D, et al. Surgical Excision of Heterotopic Ossification Leads to Re-Emergence of Mesenchymal Stem Cell Populations Responsible for Recurrence. *Stem Cells Transl Med* 2017;6:799–806. [PubMed: 28297577]

161. Dlouhy BJ, Awe O, Rao RC, et al. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: Case report. *J Neurosurg Spine* 2014;21:618–22. [PubMed: 25002238]
162. Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. *Theranostics* 2020;10:5979–97. [PubMed: 32483432]
163. Gurnathan S, Kang MH, Jeyaraj M, et al. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. *Cells* 2019;8:307.
164. Shu S, Yang Y, Allen CL, et al. Purity and yield of melanoma exosomes are dependent on isolation method. *J Extracell Vesicles* 2020;9:1692401. [PubMed: 31807236]




Figure 1.

Sources, properties, and biological functions of dental mesenchymal stem cells. Portions of this figure were made using templates from SMART SERVIER MEDICAL ART (<https://smart.servier.com>) and Biorender (<https://biorender.com/>). DPSC, dental pulp stem cells; SHED, stem cells from human exfoliated deciduous teeth; PDLSC, periodontal ligament stem cell; GMSC, gingiva-derived mesenchymal stem cell; SCAP, stem cells derived from apical papilla; DFSC, dental follicle stem cell; TGSC, tooth germ stem cell; OMF, oral and maxillofacial; CFU-f, colony forming unit-fibroblasts; CM, conditioned medium; EVs, extracellular vesicles; PBMC, peripheral blood mononuclear cell.




Figure 2. Potential application of dental MSCs and their cell-free products in tissue engineering and regenerative reconstruction of oral & maxillofacial tissue defects. Portions of this figure were made using templates from SMART SERVIER MEDICAL ART (<https://smart.servier.com>). MSC, mesenchymal stem cell; CM, conditioned medium; EVs, extracellular vesicles; TE/RM, tissue engineering/regenerative medicine.

Table 1

The search strategy summary

Items	Specification
Date of search (specified to date, month and year)	12/30/2020–2/1/2021
Databases and other sources searched	PubMed database
Search terms used (including MeSH and free text search terms and filters). Note: please use an independent supplement table to present detailed search strategy of one database as an example	Dental stem cells, oral and maxillofacial reconstruction, oral and maxillofacial tissue engineering and regeneration
Timeframe	2000–2021
Inclusion and exclusion criteria (study type, language restrictions etc.)	Articles written in English related to dental stem cells and oral and maxillofacial reconstruction were included. Any articles not written in English were excluded. No specific study type was excluded
Selection process (who conducted the selection, whether it was conducted independently, how consensus was obtained, etc.)	The selection process was done by Dr. Qinzhou Zhang
Any additional considerations, if applicable	No additional considerations

Table 2

Application of DPSC/SHED in OMF tissue regeneration

Cell type	Scaffolds/other factors	Model	Object	References
DPSC	thiol-acrylate hydrogels (Poly[ethylene glycol]-diacrylate [PEGDA] hydrogels)	Cranium defect	Rabbit	Aghali A <i>et al.</i> 2020, (76)
DPSC	E1001(1k)- β -TCP	Mandible defect	Rabbit	Zhang W <i>et al.</i> 2020, (77)
	Hydroxyapatite matrix and poly(lactic polyglycolic acid (HA/PLGA)	Mandibular defect	Rabbit	Gutiérrez-Quintero JG <i>et al.</i> 2020, (78)
SHED		Mandibular distraction, 6-weeks	Rabbit	Alkaisi A <i>et al.</i> 2013, (79)
DPSC	E1001(1k)/ β -TCP	Mandibular ramus critical bone defect, 6-weeks	Rat	Zhang W <i>et al.</i> 2016, (80)
DPSC	Silk fibroin scaffolds	Cranial bone defects	Rat	Riccio M <i>et al.</i> 2012, (81)
SHED	Collagen matrix	Maxillary alveolar defects, 2-months	Rat	Jahanbin A <i>et al.</i> 2016, (82)
DPSC	Aspirin-loaded PLGA nanoparticles	Alveolar bone defect, 28 days	Dog	Ghavimi MA <i>et al.</i> 2020, (83)
DPSC-EVs	PLGA and PEG, controlled release of DPSC-EVs	Calvarial defect	Mice	Swanson WB <i>et al.</i> 2020, (84)
DPSC sheets	4-(4-methoxyphenyl)pyrido [40,30:4,5]thieno[2,3-b] pyridine-2-carboxamide (TH)	Calvarial defect	Mice	Fujii Y <i>et al.</i> 2018, (85)
DPSC	T-mDPSCs	Calvarial defect, 3-months	Mice	Collignon AM <i>et al.</i> 2019, (86)
SHED	FGF2 primed SHED	Calvarial defect	Mice	Novais A <i>et al.</i> 2019, (87)
SHED		Calvarial defect, 12-weeks	Mice	Nakajima K <i>et al.</i> 2018, (88)
DPSC	β -TCP	Calvarial defects; 12-weeks	Rat	Annibali S <i>et al.</i> 2014, (89)
DPSC	hyaluronic-based hydrogel scaffold	Calvarial defect, 8-weeks	Rat	Petridis X <i>et al.</i> 2015, (90)
DPSC	HA/TCP	Calvarial defect	Rat	Asutay F <i>et al.</i> 2015, (91)
DPSC	Collagen gel scaffolds	Calvarial defect	Rat	Chamieh F <i>et al.</i> 2016, (92)
DPSC	PCL-BCP	Calvarial defect	Rabbit	Wongsupa N <i>et al.</i> 2017, (93)
DPSC	Particulate DBBG	Dental implant	sheep	Çolpak HA <i>et al.</i> 2019, (94)
DPSC		Dental implants, 8-weeks	Dogs	Ito K <i>et al.</i> 2011, (95)
DPSC	β -GP to CS	Cartilage, 14 days	Rat	Talaat W <i>et al.</i> 2020, (96)
DPSC	β -TCP	Periodontal defect, 3-months	Minipig	Li Y <i>et al.</i> 2019, (97)
DPSC	Cell sheet	Periodontal defect, 12-weeks	Minipig	Hu J <i>et al.</i> 2016, (98)
Autologous DPSC	β -TCP	Periodontal defect, 9-months	Human, 2 patients	Li Y <i>et al.</i> 2016, (99)
DPSC	DPSC sheet	Facial nerve, crush-injury	Rat	Ahmed MN <i>et al.</i> 2020, (100)
DPSC	PLGA artificial nerve conduits	Facial nerve, 2-months	Rat	Sasaki R <i>et al.</i> 2011, (101)
SHED-CM	Conditioned medium	Superior laryngeal nerve lesion	Rat	Tsuruta T <i>et al.</i> 2018, (102)

DPSC, dental pulp stem cells; SHED, stem cells from human exfoliated deciduous teeth; OMF, oral and maxillofacial; PLGA, poly(lactic-co-glycolic acid); PEG, poly(ethylene glycol); EV, extracellular vesicle; β -TCP, β -tricalcium phosphate; PCL, poly- ϵ -caprolactone; BCP, biphasic calcium phosphate; DBBG, deproteinized bovine bone graft; GP, glycerophosphate; CS, chitosan.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Application of PDLSCs in OMF tissue regeneration

Cell type	Scaffolds/other factors	Model	Object	References
PDLSC	Cell sheet	Periodontal defect	CB17/Icr-scld/scid	Raju R <i>et al.</i> 2020, (103)
PDLSC	Bio-Gide® membrane	Periodontal defect	Rats	Liu J <i>et al.</i> 2019, (104)
PDLSC-CM	Conditioned medium	Periodontal defect model	Rat	Nagata M <i>et al.</i> 2017, (105)
PDLSC	Gelfoam®	Periodontal fenestration defects	Rats	Han J <i>et al.</i> 2014, (106)
PDLSC	Titanium implants	Dental implant	Rat	Lin Y <i>et al.</i> 2011, (107)
DFSC/PDLSC	Cell sheets	Periodontal defect	Canine	Guo S <i>et al.</i> 2017, (108)
PDLSC	Collagen powder	Periodontal furcation defects	Minipigs	Basan T <i>et al.</i> 2017, (109)
PDLSC		Periodontitis	Dog	Park JY <i>et al.</i> 2011, (110)
PDLSC	Cell sheet	Periodontal defect	Human	Iwata T <i>et al.</i> 2018, (111)
PDLSC	Bio-Oss	Maxillary sinus floor augmentations	Dog	Yu BH <i>et al.</i> 2014, (112)
PDLSC	RGD tripeptide	Calvarial defects	Mice	Moshaverinia A <i>et al.</i> 2014, (113)
PDLSC-CM	Conditioned medium	Calvarial defect	Mice	Ogisu K <i>et al.</i> 2020, (114)
PDLSC	HA-ECM	Calvarial defects	Rat	Tour G <i>et al.</i> 2012, (115)
PDLSC	HGCCS	Calvarial defect	Rat	Ge S <i>et al.</i> 2012, (116)
PDLSC	Collagen membrane (Bio-Guide)	Calvarial defect	Rabbit	Kadkhoda Z <i>et al.</i> 2016, (117)

PDLSC, periodontal ligament stem cell; OMF, oral and maxillofacial; CM, conditioned medium; DFSC, dental follicle stem cell; RGD, arginine-glycine-aspartic acid; HA-ECM, hydroxyapatite-incorporated extracellular matrix; HGCCS, nanohydroxyapatite-coated gempinchitosan conjunction scaffold.

Table 4

Application of GMSCs in oral & craniofacial tissue regeneration

Cell type	Scaffolds/other factors	Model	Object	References
GMSC-CM	Conditioned medium	Periodontal defects	Rats	Qiu J <i>et al.</i> 2020, (122)
GMSC-EV	TNF- α pre-conditioned	Periodontal	Mice	Nakao Y <i>et al.</i> 2020, (123)
GMSC		Class III furcation defects	Dog	Yu X <i>et al.</i> 2013, (124)
GMSC	IL-1Ra HA-sECM	Periodontal defects	Minipig	Fawzy El-Sayed KM <i>et al.</i> 2015, (125)
GMSC	IV injection	Mandibular bone	Mice	Xu QC <i>et al.</i> 2014, (126)
GMSC	Alginate-based adhesive, photocrosslinkable, and osteoconductive hydrogel biomaterial (AdhHG)	Rat peri-implantitis model	Rat	Hasani-Sadrabadi MM <i>et al.</i> 2020, (127)
GMSCs	Hydrogel scaffold PuraMatrix™	Maxillary alveolar defect	Nude rats	Kandaram U <i>et al.</i> 2020, (128)
GMSC	Type I collagen	Mandibular defect	Rat	Wang F <i>et al.</i> 2011, (129)
GMSCs	Bio-Oss®/SB431542	Maxillary bone defects	minipigs	Shi A <i>et al.</i> 2019, (130)
GMSC-EV	PLA 3D printing	Calvarial defect	Rat	Pizzicannella J <i>et al.</i> 2019, (131)
GMSC-EV	(3D) engineered scaffolds (PLA)	Calvarial defect	Rat	Diomedea F <i>et al.</i> 2018, (132)
GMSC		Palatal wound	Mice	Su Y <i>et al.</i> 2018, (133)
Fetal GMSCs		Gingival defects	Rat	Li J <i>et al.</i> 2018, (134)
GMSC-EV	SIS-ECM	Tongue defects	Rat	Zhang Y <i>et al.</i> 2019, (135)
GMSC	SIS-ECM	Tongue defects	Rat	Xu Q <i>et al.</i> 2017, (136)
GMSC	3D spheroid, 3D bioprinting	Facial nerve	Rat	Zhang Q <i>et al.</i> 2018, (137)
GMSC-NCC	AxoGuard nerve conduits	Facial nerve	Rat	Zhang Q <i>et al.</i> 2018, (138)

GMSC, gingiva-derived mesenchymal stem cell; CM, conditioned medium; EV, extracellular vesicle; HA-sECM, hyaluronic acid synthetic extracellular matrix; PLA, polylactic acid; SIS-ECM, small intestinal submucosa extracellular matrix.

Table 5

The potential application of DFSCs and SCAP in OMF tissue regeneration

Cell Type	Scaffolds/other factors	Model	Object	References
DFSC-CM	Conditioned medium	Pulpitis	Rat	Hong H <i>et al.</i> 2020, (140)
DFSC	HA- β -TCP particles/cell sheets/treated dentin matrix	Calvarial defect/periodontal defect	Rat/dog	Yang H <i>et al.</i> 2019, (141)
DFSC/PDLSC	Cell sheets	Periodontal defect	Canine	Guo S <i>et al.</i> 2017, (108)
DFSC	β -TCP	Periodontal defects	Dog	Zuolin J <i>et al.</i> 2010, (144)
DFSC	Polycaprolactone scaffold	Cranial/skull defects	Rat	Rezai-Rad M <i>et al.</i> 2015, (142)
DFSC	Coralline hydroxyapatite	Alveolar bone defect	Rat	Nie L <i>et al.</i> 2017, (143)
SCAP	3D-printed hydroxyapatite scaffolds	Pulp	Nude mice	Hilkens P <i>et al.</i> 2017, (145)
SCAP-Exo		Dentinogenesis	Nude mice	Zhuang X <i>et al.</i> 2020, (146)
SCAP		Periodontitis	Minipig	Li G <i>et al.</i> 2018, (147)
SCAP	SFRP2 expressing	Periodontitis	Minipig	Li G <i>et al.</i> 2020, (148)

DFSC, dental follicle stem cell; SCAP, stem cells derived from apica papilla; OMF, oral and maxillofacial; CM, conditioned medium; PDLSC, periodontal ligament stem cell; HA, hydroxyapatite; β -TCP, β -tricalcium phosphate.

Table 6

Potential application of dental-MSC-derived EVs in OMF tissue regeneration

Cell type	Scaffolds/other factors	Model	Object	References
SHED-CM	Conditioned medium	Superior laryngeal nerve lesion	Rat	Tsuruta T <i>et al.</i> 2018, (102)
PDLSC-CM	Conditioned medium	Periodontal defect model	Rat	Nagata M <i>et al.</i> 2017, (105)
PDLSC-CM	Conditioned medium	Calvarial defect	Mice	Ogisu K <i>et al.</i> 2020, (114)
DFSC-CM	Conditioned medium	Pulpitis	Rat	Hong H <i>et al.</i> 2020, (140)
GMSC-CM	Conditioned medium	Periodontal defects	Rat	Qiu J <i>et al.</i> 2020, (122)
GMSC-CM	a poly-(lactide) (3D-PLA)	Calvarial defect	Rat	Diomedea F <i>et al.</i> 2018, (153)
DFSC-EV		Odontogenesis/Pulp	Rat	Zheng J <i>et al.</i> 2020, (154)
DFSC-EV	Treated dentin matrix	Pulp-dentin complex	Minipig	Wen B <i>et al.</i> 2020, (155)
DFSC-EV	PLGA and PEG, controlled release of DPSC-EVs	Calvarial defect	Mice	Swanson WB <i>et al.</i> 2020, (84)
GMSC-EV		Palatal wound	Mice	Kou X <i>et al.</i> 2018, (70)
GMSC-EV	SIS-ECM	Tongue defects	Rat	Zhang Y <i>et al.</i> 2019, (135)
GMSC-EV	TNF- α pre-conditioned	Periodontal	Mice	Nakao Y <i>et al.</i> 2020, (123)
GMSC-EV	PLA 3D printing	Calvarial defect	Rat	Pizzicannella J <i>et al.</i> 2019, (131)
GMSC-EV	(3D) engineered scaffolds (PLA)	Calvarial defect	Rat	Diomedea F <i>et al.</i> 2018, (132)
DFSC-EV	LPS pre-conditioned/hydrogel	Periodontal	Rat	Shi W <i>et al.</i> 2020, (156)
SCAP-EV		Dentinogenesis	Mice	Zhuang X <i>et al.</i> 2020, (146)

SHED, stem cells from human exfoliated deciduous teeth; MSC, mesenchymal stem cell; EV, extracellular vesicle; OMF, oral and maxillofacial; CM, conditioned medium; PLGA, Poly(lactic-co-glycolic acid); PEG, poly(ethylene glycol); SIS-ECM, small intestinal submucosa extracellular matrix; LPS, lipopolysaccharide.